Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.
Rubió-Casadevall J, Cirauqui Cirauqui B, Martinez Trufero J, Plana Serrahima M, García Castaño A, Carral Maseda A, Iglesias Docampo L, Pérez Segura P, Ceballos Lenza I, Gutiérrez Calderón V, Fuster Salvà J, Pena Álvarez C, Hernandez I, Del Barco Morillo E, Chaves Conde M, Martínez Galán J, Durán Sánchez M, Quiroga V, Ortega E, Mesia R. Rubió-Casadevall J, et al. Among authors: perez segura p. Front Oncol. 2023 Aug 1;13:1226939. doi: 10.3389/fonc.2023.1226939. eCollection 2023. Front Oncol. 2023. PMID: 37601652 Free PMC article.
Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer.
Cabezas-Camarero S, Merino-Menéndez S, Cabrera-Martín MN, Sotelo MJ, Plaza-Hernández JC, Falahat F, Iglesias-Moreno MC, Pérez-Segura P. Cabezas-Camarero S, et al. Among authors: perez segura p. Oncol Lett. 2022 Dec 7;25(1):37. doi: 10.3892/ol.2022.13623. eCollection 2023 Jan. Oncol Lett. 2022. PMID: 36589672 Free PMC article.
Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients.
Benitez Fuentes JD, Mohamed Mohamed K, de Luna Aguilar A, Jiménez García C, Guevara-Hoyer K, Fernandez-Arquero M, Rodríguez de la Peña MA, Garciía Bravo L, Jiménez Ortega AF, Flores Navarro P, Bartolome Arcilla J, Alonso Arenilla B, Baos Muñoz E, Delgado-Iribarren García-Campero A, Montealegre Sanz M, Sanchez-Ramon S, Perez Segura P. Benitez Fuentes JD, et al. Among authors: perez segura p. Front Oncol. 2022 Dec 20;12:975980. doi: 10.3389/fonc.2022.975980. eCollection 2022. Front Oncol. 2022. PMID: 36605446 Free PMC article.
Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer.
Cabezas-Camarero S, Iglesias-Moreno MC, Cerezo Druet E, Sotelo MJ, Merino-Menéndez S, Cabrera-Martín MN, Plaza-Hernández JC, Pérez-Segura P. Cabezas-Camarero S, et al. Among authors: perez segura p. Anticancer Drugs. 2023 Jun 1;34(5):695-698. doi: 10.1097/CAD.0000000000001422. Epub 2022 Nov 17. Anticancer Drugs. 2023. PMID: 36730545
Clinical Behavior, Mutational Profile and T-Cell Repertoire of High-Grade Neuroendocrine Tumors of the Head and Neck.
Cabezas-Camarero S, García-Barberán V, Benítez-Fuentes JD, Sotelo MJ, Plaza JC, Encinas-Bascones A, De-la-Sen Ó, Falahat F, Gimeno-Hernández J, Gómez-Serrano M, Puebla-Díaz F, De-Pedro-Marina M, Iglesias-Moreno M, Pérez-Segura P. Cabezas-Camarero S, et al. Among authors: perez segura p. Cancers (Basel). 2023 Apr 24;15(9):2431. doi: 10.3390/cancers15092431. Cancers (Basel). 2023. PMID: 37173898 Free PMC article.
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.
López de Sá A, Díaz-Tejeiro C, Poyatos-Racionero E, Nieto-Jiménez C, Paniagua-Herranz L, Sanvicente A, Calvo E, Pérez-Segura P, Moreno V, Moris F, Ocana A. López de Sá A, et al. Among authors: perez segura p. J Hematol Oncol. 2023 Dec 12;16(1):118. doi: 10.1186/s13045-023-01519-0. J Hematol Oncol. 2023. PMID: 38087293 Free PMC article. Review.
Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain.
Benitez Fuentes JD, de Luna Aguilar A, Jimenez Ortega AF, Flores Navarro P, Bartolomé Arcilla J, Baos Muñoz E, Delgado-Iribarren García-Campero A, Gil Useros S, Martinez Capella I, Llorente Sanz L, Torrego Ellacuría M, Pérez Segura P. Benitez Fuentes JD, et al. Among authors: perez segura p. F1000Res. 2022 Apr 19;11:434. doi: 10.12688/f1000research.110268.2. eCollection 2022. F1000Res. 2022. PMID: 36636471 Free PMC article.
190 results